TELA News and Press, TELA Bio Inc. From 01/14/21

TELA Bio (TELA) reports preliminary Q4 and FY 2020 results. Q4 rand FY20 revenue is expected to be $5.5M - $5.7M (consensus $6.03M) and $18.0M - 18.2M (est. $18.52M), respectively.Cash and equivalents at December 31, 2020 is expected to be $74.4M. "Our revenue in the fourth quarter conti...

MALVERN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today r...

MALVERN, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that t...

Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options MALVERN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue...

MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that t...

TELA Bio, Inc. (TELA) Q3 2020 Earnings Conference Call November 11, 2020, 04:30 PM ET Company Participants Stuart Henderson - VP, Corporate Development and IR Tony Koblish - President and CEO Nora Brennan - CFO Conference Call Participants Raj Denhoy - Jefferies Matthew O'Brien - Piper Sandle...

TELA Bio (TELA): Q3 GAAP EPS of -$0.53 misses by $0.09.Revenue of $5.31M (+33.8% Y/Y) beats by $0.73M.Press Release For further details see: TELA Bio EPS misses by $0.09, beats on revenue

MALVERN, Pa., Nov. 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today r...

MALVERN, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced today that t...

MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, ann...